bluebird bio Inc (BLUE.OQ)
BLUE.OQ on NASDAQ Stock Exchange Global Select Market
162.60USD
25 Apr 2018
162.60USD
25 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$162.60
$162.60
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
263,244
263,244
52-wk High
$236.05
$236.05
52-wk Low
$74.65
$74.65
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -2.08 | December | 26 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 6 | 6 | 5 | 6 |
| (2) OUTPERFORM | 6 | 6 | 6 | 6 |
| (3) HOLD | 7 | 7 | 7 | 7 |
| (4) UNDERPERFORM | 1 | 1 | 1 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.15 | 2.15 | 2.21 | 2.05 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 12 | 5.92 | 9.00 | 2.30 | 3.33 |
| Quarter Ending Sep-18 | 12 | 5.86 | 9.00 | 3.70 | 4.93 |
| Year Ending Dec-18 | 18 | 23.23 | 40.31 | 0.00 | 24.41 |
| Year Ending Dec-19 | 19 | 82.20 | 537.17 | 19.00 | 110.08 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 16 | -2.08 | -0.89 | -2.65 | -1.78 |
| Quarter Ending Sep-18 | 16 | -2.13 | -0.86 | -2.79 | -1.67 |
| Year Ending Dec-18 | 19 | -8.33 | -3.50 | -10.89 | -7.56 |
| Year Ending Dec-19 | 19 | -7.85 | -1.03 | -10.82 | -6.76 |
| LT Growth Rate (%) | 1 | 144.00 | 144.00 | 144.00 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 7.06 | 4.17 | 2.89 | 40.93 |
| Quarter Ending Sep-17 | 7.07 | 7.71 | 0.64 | 9.06 |
| Quarter Ending Jun-17 | 5.21 | 16.72 | 11.51 | 220.88 |
| Quarter Ending Mar-17 | 2.12 | 6.83 | 4.71 | 221.78 |
| Quarter Ending Dec-16 | 1.76 | 1.55 | 0.21 | 12.02 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -1.70 | -2.52 | 0.82 | -48.14 |
| Quarter Ending Sep-17 | -1.71 | -1.73 | 0.02 | -1.38 |
| Quarter Ending Jun-17 | -1.65 | -1.73 | 0.08 | -4.56 |
| Quarter Ending Mar-17 | -1.78 | -1.68 | 0.10 | -5.42 |
| Quarter Ending Dec-16 | -1.86 | -1.88 | 0.02 | -0.87 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5.92 | 5.93 | 5.93 | 5.60 | 3.33 |
| Quarter Ending Sep-18 | 5.86 | 5.88 | 5.88 | 5.57 | 4.93 |
| Year Ending Dec-18 | 23.23 | 23.23 | 23.23 | 23.65 | 24.41 |
| Year Ending Dec-19 | 82.20 | 81.94 | 81.94 | 89.42 | 110.08 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -2.08 | -2.08 | -2.08 | -2.03 | -1.78 |
| Quarter Ending Sep-18 | -2.13 | -2.13 | -2.12 | -2.06 | -1.67 |
| Year Ending Dec-18 | -8.33 | -8.33 | -8.30 | -8.10 | -7.56 |
| Year Ending Dec-19 | -7.85 | -7.86 | -7.83 | -7.44 | -6.76 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 1 | 0 | 1 |
| Quarter Ending Sep-18 | 0 | 1 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 1 | 0 | 1 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Sep-18 | 1 | 0 | 1 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 1 | 0 | 1 | 1 |
Earnings vs. 
Estimates- Lonza's virus factory shows gene therapy's Texas-sized promise
- FOCUS-Lonza's virus factory shows gene therapy's Texas-sized promise
- BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.
- Why Oppenheimer Global fund is focusing on biotech as rates rise
- Why Oppenheimer Global fund is focusing on biotech as rates rise